These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 3466037)

  • 1. Role of HTLV III/LAV envelope protein.
    Bicker U
    Nature; 1986 Nov 27-Dec 3; 324(6095):307. PubMed ID: 3466037
    [No Abstract]   [Full Text] [Related]  

  • 2. Prediction of HIV vaccine.
    Robson B; Fishleigh RV; Morrison CA
    Nature; 1987 Jan 29-Feb 4; 325(6103):395. PubMed ID: 3468356
    [No Abstract]   [Full Text] [Related]  

  • 3. [Detection of antibodies to the surface (anti-p-41) and nuclear protein (anti-p-24) of the human immunologic deficiency virus (HIV)].
    Hess G; Kroegel C; Ramadori G; Rieder H; Meyer zum Büschenfelde KH
    Med Klin (Munich); 1987 Oct; 82(21):723-5, 761. PubMed ID: 3500393
    [No Abstract]   [Full Text] [Related]  

  • 4. [Lymphopathic HTLV-III-LAV infection and acquired immunodeficiency syndrome].
    Pokrovskiĭ VV
    Ter Arkh; 1986; 58(10):151-4. PubMed ID: 3541273
    [No Abstract]   [Full Text] [Related]  

  • 5. Neutralizing antibodies in HIV (HTLV-III) infection: correlation with clinical outcome and antibody response against different viral proteins.
    Ranki A; Weiss SH; Valle SL; Antonen J; Krohn KJ
    Clin Exp Immunol; 1987 Aug; 69(2):231-9. PubMed ID: 3652531
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Is the HTLV III/LAV virus the causative agent of AIDS or merely an agent of one of the opportunistic infections?].
    Hollán Z
    Orv Hetil; 1986 Dec; 127(52):3219-20. PubMed ID: 2949193
    [No Abstract]   [Full Text] [Related]  

  • 7. [Anti-HTLV III/LAV antibodies of the IgM class in subjects at risk with negative anti-HTLV III/LAV IgG ELISA results (preliminary results)].
    Bedarida G; D'Agostino F; Ronsivalle MG; Berto E; Cambiè G; Berto N; Grisi ME; Arcidiacono I; Sterza G
    Riv Emoter Immunoematol; 1986; 33(1):75-87. PubMed ID: 3532290
    [No Abstract]   [Full Text] [Related]  

  • 8. Lymphadenopathic type of Kaposi's sarcoma in a Ugandan child seropositive for LAV/HTLV-III antibodies.
    Marquart KH; Müller HA; Hartter P; Oku JC; Ayuko WO
    J Trop Med Hyg; 1987 Apr; 90(2):93-4. PubMed ID: 3470530
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Laboratory assessment of HIV infection and its sequelae].
    Grob PJ
    Ther Umsch; 1988 Sep; 45(9):593-603. PubMed ID: 2903571
    [No Abstract]   [Full Text] [Related]  

  • 10. [LAV/HTLV III infection in homosexual and bisexual men--data on transmission and risk markers in Stockholm].
    Karlsson A; Bratt G; Moberg L; von Krogh G; Hedqvist B; Morfeldt JO; Böttiger B; Biberfeld G; Böttiger M; Hellström L
    Lakartidningen; 1986 Aug; 83(35):2834-7. PubMed ID: 3462445
    [No Abstract]   [Full Text] [Related]  

  • 11. Clonal selection of human immunodeficiency virus (HIV): serological differences in the envelope antigens of the cloned viruses and HIV prototypes (HTLV-III B, LAV, and ARV).
    Harada S; Kobayashi N; Koyanagi Y; Yamamoto N
    Virology; 1987 Jun; 158(2):447-51. PubMed ID: 2438845
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Extrathecal and intrathecal IgG response to the AIDS virus LAV/HTLV-III in experimental infection of chimpanzees.
    Goudsmit J; Gibbs CJ; Asher DM; Gajdusek DC
    Cancer Detect Prev Suppl; 1987; 1():509-14. PubMed ID: 3480064
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Possible use of anti-envelope immunotoxins against HIV-infection].
    Matsushita S; Koito A; Maeda Y; Hattori T; Takatsuki K
    Nihon Rinsho; 1989 Jan; 47(1):220-6. PubMed ID: 2786096
    [No Abstract]   [Full Text] [Related]  

  • 14. Testing for HTLV-III/LAV antibody.
    Holston JL
    Ala J Med Sci; 1986 Jul; 23(3):269-71. PubMed ID: 3019171
    [No Abstract]   [Full Text] [Related]  

  • 15. [LAV/HTLV-III infection among homosexual men; prevalence, incidence and possible co-factors].
    de Wolf F; Coutinho RA; Goudsmit J; Krone W; Schellekens P; Danner S
    Ned Tijdschr Geneeskd; 1986 Nov; 130(48):2180-3. PubMed ID: 3643452
    [No Abstract]   [Full Text] [Related]  

  • 16. HTLV-III neutralizing antibody development in transfusion-dependent seropositive patients with beta-thalassemia.
    Robert-Guroff M; Giardina PJ; Robey WG; Jennings AM; Naugle CJ; Akbar AN; Grady RW; Hilgartner MW
    J Immunol; 1987 Jun; 138(11):3731-6. PubMed ID: 3495568
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Anti-HTLV-III/Lav antibodies, clinical symptoms and immunological determinations in hemophilia patients in Buenos Aires].
    Anselmo A; Muchinik G; Pérez Bianco R; de la Barrera S; Riera NE; de Bracco MM; de Tezanos Pinto M
    Medicina (B Aires); 1985; 45(3):312-3. PubMed ID: 3870213
    [No Abstract]   [Full Text] [Related]  

  • 18. [Epidemiologic study of infection by the HTLV-III/LAV agent in Asturian heroin addicts, 1983-1985].
    Cartón JA; Carcaba V; Fernández-León A; Asensi V; Pérez R; Rubio S; Navia-Osorio JM; Arribas JM
    Med Clin (Barc); 1986 Oct; 87(11):448-52. PubMed ID: 3465983
    [No Abstract]   [Full Text] [Related]  

  • 19. Enhancing antibody and its role in acquired immunodeficiency syndrome.
    Robinson WE
    West J Med; 1993 Mar; 158(3):297-8. PubMed ID: 8460515
    [No Abstract]   [Full Text] [Related]  

  • 20. A stage model of HTLV-III LAV infection in intravenous drug users.
    Des Jarlais DC; Friedman SR; Spira TJ; Zolla-Pazner S; Marmor M; Holzman R; Mildvan D; Yancovitz S; Mathur-Wagh U; Garber J
    NIDA Res Monogr; 1986; 67():328-34. PubMed ID: 3018574
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.